← Back to Search

Other

NE3107 for Parkinson's Disease

Phase 1 & 2
Waitlist Available
Research Sponsored by BioVie Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up aims will be measured during the 8 hour period of observation on day 1, 2, 3, 14, and 28
Awards & highlights

Study Summary

This trial is testing a new drug for Parkinson's disease to see if it is safe and effective. The trial will last 28 days and enroll 40 patients who are currently taking medication for their Parkinson's.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~aims will be measured during the 8 hour period of observation on day 1, 2, 3, 14, and 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and aims will be measured during the 8 hour period of observation on day 1, 2, 3, 14, and 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline (day 1) in Motor disease society- Unified Parkinson's disease rating scale Part III total score for the patient in the "off-state" (without L-dopa for previous eight hours)
Change from baseline in Non-Motor Symptom Assessment Scale for Parkinson Disease (NMSS)
Change from baseline in average Motor disease society- Unified Parkinson's disease rating scale Part III total score measured over the course of 8 hours after taking L-dopa and/or NE3107
+10 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NE3107Experimental Treatment1 Intervention
orally administered NE3107 20 mg twice daily (BID)
Group II: placeboPlacebo Group1 Intervention
orally administered placebo, twice daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NE3107
2021
Completed Phase 3
~510

Find a Location

Who is running the clinical trial?

BioVie Inc.Lead Sponsor
5 Previous Clinical Trials
488 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa
2022. "NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05083260.
~14 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top